FDA approvalconf 0.99
elevidys — FDA approval
$SRPT · Sarepta Therapeutics, Inc. · Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged 4 through 5 years with a confirmed mutation in the DMD gene
Event date
June 22, 2023
1080 days ago
Sponsor runway
10 mo
$653.2M liquid
Evidence
Comparable historical fda approvals· last 5 years · same event type
100% hit rate (10/10)
| Ticker | Drug | Date | Outcome |
|---|---|---|---|
| $INCY | zynyz | 2026-05-18 | success |
| $INCY | jakafi xr | 2026-05-01 | success |
| $AXSM | auvelity | 2026-04-30 | success |
| $INCY | zynyz | 2026-03-30 | success |
| $BIIB | spinraza | 2026-03-27 | success |
| $CORT | lifyorli | 2026-03-25 | success |
| $RYTM | imcivree | 2026-03-19 | success |
| $ASND | yuviwel | 2026-02-27 | success |
| $BMRN | palynziq | 2026-02-27 | success |
| $ETON | desmoda | 2026-02-25 | success |
Recent insider activity· ±90 days
4 insiders · 6 buys · 1 sells
Buy
2023-08-14Chambers Michael Andrew
Director
4,032 @ $109.89$443K
Buy
2023-08-14Chambers Michael Andrew
Director
5,947 @ $109.19$649K
Buy
2023-08-11Chambers Michael Andrew
Director
23,686 @ $108.05$2.56M
Buy
2023-08-10Chambers Michael Andrew
Director
31,570 @ $106.26$3.35M
Buy
2023-08-10Chambers Michael Andrew
Director
2,206 @ $104.67$231K
Buy
2023-08-10Chambers Michael Andrew
Director
1,091 @ $105.90$116K
Exercise
2023-08-04Wigzell Hans Lennart Rudolf
Director
15,000 @ $29.03$435K
Sell
2023-08-04Wigzell Hans Lennart Rudolf
Director
15,000 @ $106.72$1.60M
Tax
2023-06-01Brown Ryan Edward
EVP, General Counsel
89 @ $123.60$11K
Tax
2023-03-30Arif Bilal
Chief Tech Ops Officer
307 @ $136.66$42K